Optimax Holdings (0222) Fair Value & Analysis
Healthcare · MY · Market cap 288M MYR
Fair value as of: Jun 24, 2026
Analysis
Optimax Holdings (0222) currently trades at 0.5200 MYR, while our model-based Fair Value estimate is 0.5600 MYR — implying the stock looks roughly 7.7% undervalued today. We read business quality at 89/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Optimax Holdings Berhad, an investment holding company, engages in the provision of eye specialist services and related products in Malaysia. The company's specialist centers offer a range of treatments relating to eye diseases and disorders, such as cataracts, glaucoma, refractive errors, age-related macular degeneration, diabetic retinopathy, retinal detachment, pterygium, keratoconus, dry eyes, and other eye diseases and disorders. It also provides services for treatment of myopia, amblyopia, and squint eyes for kids; eye examination, ortho-k specialist, and orthoptist services for kids; plastic surgery and aesthetic services; lasik surgery service; refractive surgery, consultation and dispensary, oculoplastic surgery, medical consumable and eye examination services. In addition, the company markets food products; and retails pharmaceuticals, medical, orthopaedic goods, perfumery, cosmetics, and toilet articles. Further, it offers medical services related to ear, nose and throat;…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Optimax Holdings (0222) undervalued?
What is the fair value of 0222?
What is the quality score of 0222?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.